The regulation of fecal microbiota for transplantation: An international perspective for policy and public health

Clinical Research and Regulatory Affairs

Volumn 32, Issue 3, 2015, Pages 101-109

  Edelstein, Carolyn A ^a   Kassam, Zain ^a,b   Daw, Jamie ^c   Smith, Mark B ^a,b   Kelly, Colleen R ^d  

^a OpenBiome   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c HARVARD UNIVERSITY   (United States)

^d BROWN UNIVERSITY   (United States)

Author keywords

Clostridium difficile; fecal microbiota transplantation (FMT); Health Canada; microbiome; US Food and Drug Administration (FDA)

Indexed keywords

ANTIBIOTIC AGENT; BIOLOGICAL PRODUCT; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; VANCOMYCIN;

ANTIBIOTIC THERAPY; AUSTRALIA; BLOOD; BLOOD TRANSFUSION; CANADA; CHINA; CLINICAL TRIAL (TOPIC); CLOSTRIDIUM DIFFICILE INFECTION; COST EFFECTIVENESS ANALYSIS; CRYOPRESERVATION; EUROPE; EXPERIMENTAL THERAPY; FECAL MICROBIOTA TRANSPLANTATION; FECES; FECES ANALYSIS; FECES MICROFLORA; FOOD AND DRUG ADMINISTRATION; HEALTH CARE; HEALTH CARE POLICY; HEALTH SERVICE; HUMAN; INTESTINE FLORA; META ANALYSIS; MULTICENTER STUDY (TOPIC); PATENT; PATIENT SAFETY; PHYSICIAN; PUBLIC HEALTH; PUBLIC HEALTH SERVICE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCIENTIST; TISSUE TRANSPLANTATION; TISSUES; UNITED STATES; WESTERN EUROPE;

EID: 84940529097     PISSN: 10601333     EISSN: 15322521     Source Type: Journal    
DOI: 10.3109/10601333.2015.1046602     Document Type: Review

References (67)

1. Eckburg PB, Bik EM, Bernstein CN, et al. Diversity of the human intestinal microbial flora. Science 2005;308:1635-8.
2. Lozupone CA, Stombaugh JI, Gordon JI, et al. Diversity, stability and resilience of the human gut microbiota. Nature 2012;489: 220-30.
3. Kassam Z, Lee CH, Hunt RH. Review of the emerging treatment of clostridium difficile infection with fecal microbiota transplantation and insights into future challenges. Clin Lab Med 2014;34:787-98.
4. Collins SM, Kassam Z, Bercik P. The adoptive transfer of behavioral phenotype via the intestinal microbiota: experimental evidence and clinical implications. Curr Opin Microbiol 2013;16: 240-5.
5. Vos WM de, Vos EA de. Role of the intestinal microbiome in health and disease: from correlation to causation. Nutr Rev 2012;70(Suppl 1):S45-56.
6. Ritchie ML, Romanuk TN. A meta-analysis of probiotic efficacy for gastrointestinal diseases. PLoS ONE 2012;7:e34938.
7. Zhang F, Luo W, Shi Y, et al. Should we standardize the 1,700-year-old fecal microbiota transplantation? Am J Gastroenterol 2012;107:1755-1755.
8. Smith MB, Kelly C, Alm EJ. Policy: how to regulate faecal transplants. Nature 2014;506:290-1.
9. Magill SS, Edwards JR, Bamberg W, et al. Multistate Point-Prevalence Survey of health care-associated infections. N Engl J Med 2014;370:1198-208.
10. Kuijper EJ, Coignard B, Tüll P. The ESCMID Study Group for Clostridium difficile (ESGCD), EU Member States and the European Centre for Disease Prevention and Control (ECDC). Emergence of Clostridium difficile-associated disease in North America and Europe. Clin Microbiol Infect 2006;12:2-18.
11. O'Horo JC, Jindai K, Kunzer B, Safdar N. Treatment of recurrent Clostridium difficile infection: a systematic review. Infection 2013; 42:43-59.
12. Petrella LA, Sambol SP, Cheknis A, et al. Decreased cure and increased recurrence rates for Clostridium difficile infection caused by the epidemic C. difficile BI Strain. Clin Infect Dis 2012;55: 351-7.
13. Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus Vancomycin for Clostridium difficile Infection. N Engl J Med 2011;364:422-31.
14. Pépin J, Alary M-E, Valiquette L, et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis 2005;40:1591-7.
15. Song Y, Garg S, Girotra M, et al. Microbiota dynamics in patients treated with fecal microbiota transplantation for recurrent Clostridium difficile infection. PLoS ONE 2013;8:e81330.
16. Chang JY, Antonopoulos DA, Kalra A, et al. decreased diversity of the fecal microbiome in recurrent Clostridium difficile- Associated diarrhea. J Infect Dis 2008;197:435-8.
17. Khoruts A, Dicksved J, Jansson JK, Sadowsky MJ. Changes in the composition of the human fecal microbiome after bacteriotherapy for recurrent Clostridium difficile-associated diarrhea. J Clin Gastroenterol 2010;44:354-60.
18. Moayyedi P, Marshall JK, Yuan Y, Hunt R. Canadian Association of Gastroenterology position statement: fecal microbiota transplant therapy. Can J Gastroenterol Hepatol 2014;28:66-8.
19. Kassam Z, Lee CH, Yuan Y, Hunt RH. Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta-analysis. Am J Gastroenterol 2013;108:500-8.
20. Brandt LJ, Aroniadis OC, Mellow M, et al. Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection. Am J Gastroenterol 2012;107:1079-87.
21. Sha S, Liang J, Chen M, et al. Systematic review: faecal microbiota transplantation therapy for digestive and nondigestive disorders in adults and children. Aliment Pharmacol Ther 2014;39:1003-32.
22. Van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013; 368:407-15.
23. Fischer M, Cook G, Rogers N, et al. Rescue therapy with fecal microbiota transplantation in hospitalized patients with severe and severe-complicated Clostridium difficile infection. Am J Gastroenterol 2014;109:S195.
24. Colman RJ, Rubin DT. Fecal microbiota transplantation as therapy for inflammatory bowel disease: a systematic review and metaanalysis. J Crohns Colitis 2014;8:1569-81.
25. Brandt LJ, Aroniadis OC. An overview of fecal microbiota transplantation: techniques, indications, and outcomes. Gastrointest Endosc 2013;78:240-9.
26. Vrieze A, Van Nood E, Holleman F, et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 2012;143: 913-16.e7.
27. Qin J, Li R, Raes J, et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 2010;464:59-65.
28. David LA, Materna AC, Friedman J, et al. Host lifestyle affects human microbiota on daily timescales. Genome Biol 2014;15:R89.
29. Gill SR, Pop M, DeBoy RT, et al. Metagenomic Analysis of the Human Distal Gut Microbiome. Science 2006;312:1355-9.
30. Caporaso JG, Lauber CL, Costello EK, et al. Moving pictures of the human microbiome. Genome Biol 2011;12:R50.
31. How to safely do a fecal transplant at home-DIY Instructions [Internet]. The Power of Poop, 2013. Available online at: http://thepowerofpoop.com/epatients/fecal-transplant-instructions/, accessed 13 January 2015.
32. HomeFMT. FECAL TRANSPLANT (FMT) [Internet]. 2013. Available online at: https://www.youtube.com/watch?v= xLIndT7fuGo&feature=youtube-gdata-player, accessed 31 January 2015.
33. Radley DC, Finkelstein SN, Stafford RS. Off-label prescribing among office-based physicians. Arch Intern Med 2006;166:1021-6.
34. Stafford RS. Regulating off-label drug use - Rethinking the role of the FDA. N Engl J Med 2008;358:1427-9.
35. Ley RE, Peterson DA, Gordon JI. Ecological and evolutionary forces shaping microbial diversity in the human intestine. Cell 2006;124:837-48.
36. Bäckhed F, Ley RE, Sonnenburg JL, et al. Host-bacterial mutualism in the human intestine. Science 2005;307:1915-20.
37. Baquero F, Nombela C. The microbiome as a human organ. Clin Microbiol Infect 2012;18:2-4.
38. Center for Biologics Evaluation and Research. Tissue Guidances-Guidance for industry: eligibility determination for donors of human cells, tissues, and cellular and tissue-based products [Internet]. Rockville, MD: US Food Drug Adm.; 2010. Available online at: http://www.fda.gov/BiologicsBloodVaccines/GuidanceCompliance RegulatoryInformation/Guidances/Tissue/ucm073964.htm, accessed 31 January 2015.
39. Human cells, tissues, and cellular and tissue-based products. 21 C.F.R. x 1271.3 (2001).
40. Koenig JE, Spor A, Scalfone N, et al. Succession of microbial consortia in the developing infant gut microbiome. Proc Natl Acad Sci 2011;108(Suppl 1):4578-85.
41. Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. Nature 2012;486: 207-14.
42. Cho I, Blaser MJ. The Human Microbiome: at the interface of health and disease. Nat Rev Genet 2012;13:260-70.
43. Center for Biologics Evaluation and Research. Regulation of Tissues-Tissue Reference Group [Internet]. Silver Spring, MD: US Food Drug Adm. Available online at: http://www.fda.gov/biologicsbloodvaccines/tissuetissueproducts/regulationoftissues/ucm152857.htm, accessed accessed 31 January 2015.
44. Center for Biologics Evaluation and Research. Blood safety & availability-Keeping Blood transfusions safe: FDA's multi-layered protections for donated blood [Internet]. Silver Spring, MD: US Food Drug Admin.; 2013. Available online at: http://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/BloodSafety/ucm095522.htm, accessed accessed 31 January 2015.
45. Biological Products: General. 21 C.F.R. x 600 (1973).
46. Swanson KW. Banking on the Body. Cambridge, MA: Harvard University Press; 2014.
47. Center for Biologics Evaluation and Research. Cord Blood Banking-Information for Consumers [Internet]. Silver Spring, MD: US Food Drug Adm.; 2012. Available online at: http://www. fda.gov/BiologicsBloodVaccines/ResourcesforYou/Consumers/ucm236044.htm, accessed 31 January 2015.
48. American Society for Reproductive Technology. Summary of "Eligibility Determination For Donors Of Human Cells, Tissues, And Cellular And Tissue-Based Products" [Internet]. Birmingham, AL: Society for Assisted Reproductive Technology; 2006. Available online at: http://www.sart.org/news/article.aspx?id=337, accessed 8 April 2015.
49. Whoriskey P. Anemia drug made billions, but at what cost? [Internet]. Washington DC: Washington Post; 2012. Available online at: http://www.washingtonpost.com/business/economy/anemia-drug-made-billions-but-at-what-cost/2012/07/19/gJQAX5yqwW-story.html, accessed 16 April 2015.
50. Center for Biologics Evaluation and Research (FDA), The National Institute for Allergy and Infectious Diseases (NIH). Fecal microbiota for transplantation: scientific and regulatory issues [Internet]. Bethesda, MD: Food and Drug Administration; 2013. Available online at: http://www.fda.gov/downloads/BiologicsBloodVaccines/NewsEvents/WorkshopsMeetingsConferences/UCM352902.pdf, accessed 31 January 2015.
51. Center for Biologics Evaluation and Research. Guidance for Industry: enforcement policy regarding investigational new drug requirements for use of fecal microbiota for transplantation to treat clostridium difficile infection not responsive to standard therapies [Internet]. Silver Spring, MD: US Food Drug Adm.; 2013. Available online at: http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm361379.htm, accessed 3 February 2015.
52. Center for Biologics Evaluation and Research. Draft guidance for industry: enforcement policy regarding investigational new drug requirements for use of fecal microbiota for transplantation to treat Clostridium difficile infection not responsive to standard therapies. [Internet]. Silver Spring, MD: US Food Drug Adm.; 2014. Available online at: http://www.fda.gov/biologicsbloodvaccines/guidancecomplianceregulatoryinformation/guidances/vaccines/ucm387023.htm, accessed 3 February 2015.
53. Guidance for Industry: Enforcement policy regarding investigational new drug requirements for use of fecal microbiota for transplantation to treat Clostridium difficile infection not responsive to standard therapies. Fed Regist [Regulation on the Internet]. 2014 Feb 20 [cited Jan 31 2015];79:10814-15. Available from: http://www.regulations.gov/#!documentDetail;D=FDA-2013-D-0811-0003.
54. Allen-Vercoe E, Reid G, Viner N, et al. A Canadian Working Group report on fecal microbial therapy: microbial ecosystems therapeutics. Can J Gastroenterol 2012;26:457-62.
55. Government of Canada. guidance document for clinical trial sponsors: clinical trial applications [Internet]. Ottawa, ON: Health Canada; 2003. Available online at: http://www.hc-sc.gc.ca/dhp-mps/prodpharma/applic-demande/guide-ld/clini/ctdcta-ctddeceng. php, accessed 3 February 2015.
56. Stueck W. B.C. health authority halts fecal transplants [Internet]. Toronto ON: Globe Mail; 2014. Available online at: http://www.theglobeandmail.com/news/british-columbia/health-authority-halts-fecal-transplants/article18317566/, accessed 3 February 2015.
57. Government of Canada. Guidance Document: regulation of fecal microbiota therapy for the treatment of C. difficile Infections [Internet]. Ottawa, ON: Health Canada; 2015. Available online at: http://www.hc-sc.gc.ca/dhp-mps/consultation/biolog/fecal-microbiota-bacterio-fecale-eng.php, accessed 11 April 2015.
58. Fees for the review of drug submissions, supplements, and applications [Internet]. Government of Canada: Health Canada; 2009. Available online at: http://www.hc-sc.gc.ca/dhp-mps/prodpharma/applic-demande/form/feef-fraisf-eng.php, accessed 3 February 2015.
59. Debast SB, Bauer MP, Kuijper EJ. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect Dis. 2014;20(Suppl 2):1-26.
60. National Institute for Health and Care Excellence. Faecal microbiota transplant for recurrent Clostridium difficile infection [Internet]. NICE Interv. Proced. Guid. IPG485. London, UK: National Institute for Health and Care Excellence; 2014. Available online at: https://www.nice.org.uk/guidance/ipg485, accessed 3 February 2015.
61. comité scientifique spécialisé temporaire (CSST) «Transplantation de microbiote fécal». La transplantation de microbiote fécal et son encadrement dans les essais cliniques [Internet]. Paris, France: L'Agence nationale de sécurité du médicament et des produits de santé (ANSM); 2014. Available online at: http://ansm.sante.fr/var/ansm-site/storage/original/application/5e5e01018303790194275 ded0e02353c.pdf, accessed 21 January 2015.
62. Hogg G. Comments on the New Regulatory Framework for IVDs including on the proposed amendments [Internet]. Symonston, Australia: Therapeutic Goods Administration; 2013. Available online at: https://www.tga.gov.au/sites/default/files/consult-ivdregulatory-framework-130503-submission-mdu-phl.pdf, accessed 7 January 2015.
63. Borody TJ, Paramsothy S, Agrawal G. Fecal Microbiota Transplantation: indications, methods, evidence, and future directions. Curr Gastroenterol Rep [Internet] 2013;15: Available online at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3742951/, accessed 9 February 2015.
64. Zhang F. Interview about the regulation of FMT in China with Dr. Zhang of the Medical Center for Digestive Diseases, the Second Affiliated Hospital of Nanjing University in Nanjing, China. 2014.
65. Konijeti GG, Sauk J, Shrime MG, et al. Cost-effectiveness of competing strategies for management of recurrent Clostridium difficile infection: a decision analysis. Clin Infect Dis 2014;58:1507-14.
66. Antibiotic Resistance Threats in the United States, 2013 [Internet]. Atlanta, GA: Centers for Disease Control and Prevention; 2013. Available online at: http://www.cdc.gov/drugresistance/threatreport-2013/pdf/ar-threats-2013-508.pdf, accessed 7 January 2015.
67. Megerlin F, Fouassier E, Lopert R, Bourlioux P. Faecal microbiota transplantation: a sui generis biological drug, not a tissue. Ann Pharm Fr 2014;72:217-20.